Related Experiment Video

Updated: May 10, 2026

Tropomodulin 3 Overexpression as a Marker for Platinum Resistance and Immune Infiltration in Ovarian Cancer
09:40

Tropomodulin 3 Overexpression as a Marker for Platinum Resistance and Immune Infiltration in Ovarian Cancer

Published on: August 2, 2024

3-Deazaneplanocin A is a promising therapeutic agent for ovarian cancer cells

Liang Shen1, Jing Cui, Ying-Xin Pang

  • 1Department of Obstetrics and Gynaecology, Provincial Hospital Affiliated to Shandong University, Shandong, China.

Asian Pacific Journal of Cancer Prevention : APJCP
|June 28, 2013
PubMed
Abstract

Insights

3-deazaneplanocin A (DZNep) shows promise for ovarian cancer treatment by inhibiting cancer cell proliferation, inducing apoptosis, and reducing migration. This histone methyltransferase inhibitor effectively targets A2780 ovarian cancer cells.

Area of Science:

  • Oncology
  • Molecular Biology
  • Epigenetics

Background:

  • 3-deazaneplanocin A (DZNep) is a known histone methyltransferase inhibitor that targets polycomb-repressive complex 2 (PRC2).
  • DZNep has demonstrated efficacy in inhibiting proliferation, metastasis, and inducing apoptosis in various cancer types.
  • The effects of DZNep on ovarian cancer cells remain largely unexplored.

Purpose of the Study:

  • To investigate the effects of DZNep on ovarian cancer cells.
  • To evaluate DZNep's potential as a therapeutic agent for ovarian cancer.

Main Methods:

  • In vitro study of DZNep-treated A2780 ovarian cancer cells.
  • Assessment of cell proliferation using MTT assay.
  • Flow cytometry was used to measure apoptosis.
  • Cell migration was evaluated using wound healing assays.
  • Quantitative PCR (q-PCR) was employed to analyze E-cadherin gene expression.

Main Results:

  • DZNep significantly inhibited the proliferation of A2780 ovarian cancer cells.
  • DZNep treatment led to the induction of apoptosis in ovarian cancer cells.
  • Cell migration was suppressed by DZNep.
  • DZNep treatment resulted in increased expression of the migration-related gene, E-cadherin (P<0.05).

Conclusions:

  • DZNep exhibits significant potential as a therapeutic agent for ovarian cancer.
  • DZNep effectively inhibits ovarian cancer cell proliferation and migration.
  • DZNep induces apoptosis and modulates E-cadherin expression in ovarian cancer cells.

More Related Videos

Evaluating the Angiogenetic Properties of Ovarian Cancer Stem-Like Cells using the Three-Dimensional Co-Culture System, NICO-107:59

Evaluating the Angiogenetic Properties of Ovarian Cancer Stem-Like Cells using the Three-Dimensional Co-Culture System, NICO-1

Published on: December 5, 2020

Heterotypic Three-dimensional In Vitro Modeling of Stromal-Epithelial Interactions During Ovarian Cancer Initiation and Progression12:42

Heterotypic Three-dimensional In Vitro Modeling of Stromal-Epithelial Interactions During Ovarian Cancer Initiation and Progression

Published on: August 28, 2012

Related Concept Videos

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists01:27

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists

5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates these...
Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists01:29

Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists

Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Chemotherapy-Induced Nausea and Vomiting: Cannabinoids01:21

Chemotherapy-Induced Nausea and Vomiting: Cannabinoids

Tetrahydrocannabinol (THC) is a phytocannabinoid that primarily interacts with the CB1 receptor, a type of G protein-coupled receptor (GPCR) predominantly in and around the chemoreceptor trigger zone (CTZ) and emetic center. THC also blocks the serotonin receptor activity in the dorsal vagal complex (DVC) by inhibiting serotonin release. THC exerts its anti-emetic effects through these interactions, which are beneficial for patients undergoing chemotherapy.
Two synthetic agonists of THC,...
Hormonal Control of the Ovarian Cycle01:30

Hormonal Control of the Ovarian Cycle

The ovarian cycle is meticulously regulated by the hypothalamic-pituitary-gonadal axis. This cycle orchestrates the release of a mature oocyte, essential for reproduction.
Before puberty, the hypothalamus releases GnRH in a low frequency, low amplitude pulsatile manner. This along with the immature hypothalamic-pituitary-gonadal axis activity, results in low estrogen levels and the absence of a fully functional ovarian cycle.  At puberty, GnRH secretion increases in both frequency and...